 Activating mutations of the BRAF gene have been observed in a variety of cancers, including 55-68 of malignant melanomas. In general, oncogenic mutations of BRAF correlate with a poor outcome. PLX4032 is a compound that selectively inhibits oncogenic B-Raf kinase. 